Detalhe da pesquisa
1.
A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.
Cancer
; 123(23): 4556-4565, 2017 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28832976
2.
Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Oncologist
; 22(7): 780-e65, 2017 07.
Artigo
Inglês
| MEDLINE | ID: mdl-28592620
3.
A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.
Cancer
; 118(19): 4795-800, 2012 Oct 01.
Artigo
Inglês
| MEDLINE | ID: mdl-22437754
4.
Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors.
Oncology
; 81(2): 65-72, 2011.
Artigo
Inglês
| MEDLINE | ID: mdl-21968463
5.
Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers.
Clin Cancer Res
; 25(3): 937-945, 2019 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30563938
6.
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.
Cancer Chemother Pharmacol
; 82(3): 429-440, 2018 09.
Artigo
Inglês
| MEDLINE | ID: mdl-29971467
7.
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
Eur J Cancer
; 89: 19-26, 2018 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29223478
8.
Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225.
Semin Oncol Nurs
; 18(2 Suppl 2): 30-5, 2002 May.
Artigo
Inglês
| MEDLINE | ID: mdl-12053862
9.
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
J Clin Oncol
; 32(6): 513-8, 2014 Feb 20.
Artigo
Inglês
| MEDLINE | ID: mdl-24419115
10.
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.
J Clin Oncol
; 28(27): 4240-6, 2010 Sep 20.
Artigo
Inglês
| MEDLINE | ID: mdl-20713879
11.
Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).
Anticancer Res
; 30(10): 4209-17, 2010 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-21036743
12.
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.
Invest New Drugs
; 26(1): 45-51, 2008 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-17924057
13.
Bevacizumab 5 mg/kg can be infused safely over 10 minutes.
J Clin Oncol
; 25(19): 2691-5, 2007 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-17602073
14.
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
J Clin Oncol
; 25(29): 4557-61, 2007 Oct 10.
Artigo
Inglês
| MEDLINE | ID: mdl-17876013